LONDON (Reuters) – Europe’s drug regulator is investigating 62 cases worldwide of a rare blood clotting condition which has prompted some countries to limit the use of AstraZeneca’s COVID-19 vaccine, its chief Emer Cooke said in a briefing on Wednesday.
That includes 44 cases in the European Economic Area out of a total of 9.2 million people who have received the vaccine in the region, she said.
The total cited by the European Medicines Agency (EMA) does not include all the cases of the condition, known as cerebral venous sinus thrombosis (CVST), which have been reported in Germany, she said.
(Reporting by Pushkala Aripaka, Ludwig Burger and Josephine Mason; Editing by Gareth Jones)
